STAT1d
Pharmalittle: We’re reading about FDA morale, pharma removing DEI goals, and more
Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...
FierceBiotech1d
Genentech archives diversity reports amid site update, examines ‘potential implications of executive orders’
Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...
Drugmaker Roche’s US Biotech Unit Pulls DEI Targets From Website
Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly traded companies to bow to US President Donald Trump’s push against equal ...
Roche upgraded to Buy from Neutral at UBS
UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...
FiercePharma2d
Roche scores FDA nod for Evrysdi tablets, bolstering convenience edge over rivals
Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...
Roche announces FDA approves Evrysdi tablet to treat SMA
Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...
Genomic Data Analysis and Interpretation Market Research 2025-2033: Syngenta Group Leads, Followed by Amgen, Monsanto (Bayer), and Illumina
The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...
News Medical3d
Machine learning tool predicts cancer treatment response based on genetic mutations
A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes-insights that could help doctors ...
ascopubs.org4d
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...